GNTA: רווח נקי למניה (EPS TTM) Genenta Science SpA

Genenta Science S.p.A. bases its development on bioethics and environmental safety when creating cellular therapies. The change in rolling net income per share demonstrates capital dynamics, where the current value of the indicator is -0.37. High R&D expenditures and patents for viral vectors create an insurmountable barrier to entry, protecting the company's developments from new competitors in oncology.

Genenta Science S.p.A. is investing in innovative gene therapy delivery to combat glioblastoma. Net earnings per share over the last four quarters reflect the final financial result distributed across the total volume of the issue. Growth in this indicator confirms the effectiveness of cost management while scaling clinical trials. A declining trend signals expanding operating expenses. The dynamics of this metric directly determine the investment attractiveness of the market capitalization.